Leerink Partners Begins Coverage on Zimmer Biomet (NYSE:ZBH)

Key Points

• Leerink Partners initiated coverage of Zimmer Biomet with a market perform rating and a $101 price target, implying roughly an 8.44% upside from the prior close.
• The company slightly beat quarterly expectations (EPS $2.42 vs. $2.38; revenue $2.24B, +10.9% YoY) and set FY2026 guidance of EPS $8.30–$8.45, versus analyst forecasts around $8.22.
• Analyst sentiment is mixed: MarketBeat shows an average rating of Hold with a $105.95 average target, while broker actions range from upgrades (TD Cowen, Citigroup) to a cut to Sell by Goldman Sachs ( $93 target).

Stock analysts at Leerink Partners assumed coverage on shares of Zimmer Biomet (NYSE:ZBH - Get Free Report) in a note issued to investors on Monday,Benzinga reports. The brokerage set a "market perform" rating and a $101.00 price target on the medical equipment provider's stock. Leerink Partners' price objective suggests a potential upside of 8.44% from the company's previous close.

ZBH has been the subject of several other reports. TD Cowen upgraded Zimmer Biomet from a "hold" rating to a "buy" rating in a research report on Monday, January 26th. Citigroup restated a "buy" rating on shares of Zimmer Biomet in a research note on Wednesday, February 11th. Wall Street Zen raised shares of Zimmer Biomet from a "hold" rating to a "buy" rating in a research report on Saturday. The Goldman Sachs Group cut shares of Zimmer Biomet from a "neutral" rating to a "sell" rating and set a $93.00 target price on the stock. in a report on Friday, January 9th. Finally, William Blair started coverage on shares of Zimmer Biomet in a research report on Friday, February 20th. They issued a "market perform" rating for the company. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, twelve have given a Hold rating and three have given a Sell rating to the company. According to MarketBeat, Zimmer Biomet has an average rating of "Hold" and an average target price of $105.95.

Zimmer Biomet Trading Up 0.0%

Shares of Zimmer Biomet stock opened at $93.14 on Monday. The stock has a market cap of $18.03 billion, a P/E ratio of 26.31, a P/E/G ratio of 1.90 and a beta of 0.61. The company has a quick ratio of 1.10, a current ratio of 1.98 and a debt-to-equity ratio of 0.55. Zimmer Biomet has a 12-month low of $84.59 and a 12-month high of $108.29. The business's 50 day moving average is $92.92 and its 200-day moving average is $93.34.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last issued its earnings results on Tuesday, February 10th. The medical equipment provider reported $2.42 earnings per share for the quarter, topping analysts' consensus estimates of $2.38 by $0.04. Zimmer Biomet had a net margin of 8.56% and a return on equity of 12.93%. The business had revenue of $2.24 billion for the quarter, compared to the consensus estimate of $2.22 billion. During the same period in the previous year, the company earned $2.31 earnings per share. The firm's revenue for the quarter was up 10.9% on a year-over-year basis. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. Equities research analysts predict that Zimmer Biomet will post 8.22 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Zimmer Biomet news, SVP Lori Winkler sold 2,650 shares of the stock in a transaction that occurred on Thursday, March 12th. The stock was sold at an average price of $94.66, for a total transaction of $250,849.00. Following the transaction, the senior vice president directly owned 10,224 shares in the company, valued at approximately $967,803.84. This represents a 20.58% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 1.28% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Zimmer Biomet

Several institutional investors have recently made changes to their positions in the stock. M&T Bank Corp increased its position in shares of Zimmer Biomet by 15,705.6% during the fourth quarter. M&T Bank Corp now owns 3,571,595 shares of the medical equipment provider's stock worth $321,158,000 after acquiring an additional 3,548,998 shares in the last quarter. Norges Bank acquired a new position in Zimmer Biomet during the 4th quarter valued at about $221,234,000. Franklin Resources Inc. boosted its stake in Zimmer Biomet by 43.2% during the 4th quarter. Franklin Resources Inc. now owns 6,685,987 shares of the medical equipment provider's stock valued at $601,204,000 after purchasing an additional 2,017,857 shares during the last quarter. Auto Owners Insurance Co increased its holdings in Zimmer Biomet by 8,892.0% during the 4th quarter. Auto Owners Insurance Co now owns 2,009,712 shares of the medical equipment provider's stock worth $180,713,000 after purchasing an additional 1,987,362 shares in the last quarter. Finally, Dodge & Cox increased its holdings in Zimmer Biomet by 5.1% during the 3rd quarter. Dodge & Cox now owns 23,216,173 shares of the medical equipment provider's stock worth $2,286,793,000 after purchasing an additional 1,118,710 shares in the last quarter. Institutional investors and hedge funds own 88.89% of the company's stock.

About Zimmer Biomet

Zimmer Biomet NYSE: ZBH is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company's product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.